MORE Health Love Medical Pass wants to quickly copy the mature experience in the United States to Japan.

MORE Health Establishes a joint venture with Japan Integrity Healthcare to develop medical treatment in Japan

Recently, MORE Health, a well-known global digital medical service organization, and Japanese medical technology company Integrity Healthcare established a joint venture, International Healthcare, dedicated to creating a professional Chinese-Japanese medical platform and tailor-made comprehensive medical services for Chinese patients.

Previously, as a medical institution headquartered in Silicon Valley, MORE Health has established a stable cooperative relationship with the top 10 medical institutions in the United States and the specialty rankings and excellent doctors in various fields. Based on its rich medical resources in the United States, it provides high-quality medical services from the United States to patients worldwide.

The cooperation between the two companies in China and Japan means that MORE Health will further expand its service scope and further promote the accessibility of global quality medical resources to domestic consumers.

Data shows that in recent years, domestic consumers and patients’ demand for cross-border medical care has doubled, and the size of the cross-border medical service market will exceed 10 billion in the future.

Behind the blue ocean market is the difference between the standard of physical examination and the survival rate of critical illness at home and abroad. Compared with developed countries such as Europe, the United States, and Japan, the five-year survival rate of high-incidence malignant tumors in China is still far away.

The 2016 World Health Report of the World Health Organization shows that through a comprehensive comparison of the medical systems of countries around the world, in terms of “medical standards”, “difficulty in receiving medical services”, and “equity of medical expenses burden” Japan has topped this list for reasons such as “high-quality medical services” and “equality in the medical burden” and “high national life expectancy.”

In the 2018 Global Medical Quality and Accessibility Ranking published by The Lancet, Japan also performed best in all Asian countries.

Muto Mayu, Chairman of Integrity Healthcare, has previously worked at the University of Tokyo Medical School Affiliated Hospital and Mitsui Memorial Hospital, and has entered the Imperial Palace as the Emperor of Japan. When Muto left McKinsey, he founded Integrity Healthcare. Integrity Healthcare is the goalFormer largest telemedicine service provider in Japan.

MORE Health Established a joint venture with Japan Integrity Healthcare to develop medical services to Japan

Mayu Muto, Chairman of Integrity Healthcare

Muto Shinto said in an interview with 36Kr that in the future, the joint venture company ’s International Healthcare business will mainly focus on medical examination services, medical services and living services.

In addition to the medical services that were commonly used in Japan in the past, medical services will also provide services such as second consultation and video consultation. Patients can decide whether to go to Japan. If they choose to stay in China for treatment, It can help patients to implement the schemes developed by Japanese experts in Chinese domestic cooperative hospitals.

In the choice of medical institutions to go to Japan, Integrity Healthcare has already cooperated with several top Japanese medical institutions such as St. Luke International Hospital, QST Hospital, National Cancer Research Center East Hospital, etc.

Because the medical examination business is different from the intensive care service, it is mainly for healthy people. Based on the medical examination business, the joint venture company also provides travel support services to meet the relevant needs of consumers and provide full-process services.

In the medical examination service, taking breast cancer as an example, breast cancer currently ranks first in morbidity and mortality among women worldwide. It can be described as the “number one killer” of female cancer, and breast cancer can Healing is achieved through early diagnosis and early treatment. The World Health Organization has made clear that early diagnosis and early treatment is the best way to improve the cure rate of breast cancer. However, due to the denseness of female glands in China and the lack of standardized screening pathways, the early detection rate of breast cancer in China is still less than 20%.

At present, there are PEM tests for breast cancer in Japanese physical examination services, which have good sensitivity and specificity, and can detect small lesions that are difficult to capture by conventional tests. Unlike mammography, it is performed in a prone position with little compression on the breast.

When talking about the advantages of physical examination in Japan, Muto believes that since Japan began implementing anti-cancer programs in 1984, Japan has accumulated valuable experience in a large number of medical examination services and a large amount of data generated by physical examinations, and many diseases can already achieve early Discover early treatment.

In terms of intensive care, Muto said that currentlyThe five-year survival rate of Japanese patients with lung cancer, stomach cancer, liver cancer, and esophageal cancer with a higher incidence in China is significantly higher than that of Chinese patients [2].

Radiation therapy is one of the three major weapons for tumor treatment. According to statistics from professional radiotherapy media, in the field of proton heavy ion therapy, as of April this year, there have been 23 domestic proton heavy ion treatment centers in China. Only Shanghai Proton Heavy Ion Hospital was put into use.

Compared to medical treatment in the United States, Japan’s medical advantages are mainly reflected in the fact that the number of nurses per 1,000 people and the number of beds in Japan are higher than those in the United States, and nursing services are an important part of the rehabilitation treatment of critically ill patients.

While the five-year survival rate of some tumors is higher than that of the United States [2], Muto said that the cost of some cancer drugs, living costs and transportation costs in Japan are now more economical than going to the United States.

Previously, some Japanese medical institutions were unable to receive foreign patients due to language issues and insurance issues. However, as Japan began to promote international medical services in 2013, promoted Japanese medical resources, established a medical advancement committee to Japan, and established the JIH International Hospital Accreditation System. At present, Japanese medical institutions have accumulated some experience in receiving international patients.

“In the future, the market size of medical treatment in Japan will further expand as the Japanese government relaxes visa policies and increases investment in medical resources. The Medical Committee in Japan will also assist medical institutions to receive foreign patients and promote medical resources in the future. In addition to the introduction of the JCI International Hospital Accreditation System, it has also developed its own international hospital accreditation system, which has increased the visibility of more medical institutions overseas. “

Muto Mayu is also the chairman of the Japan Medical Promotion Committee to Japan. He believes that Japan’s previous investment in medical resources has not reached the level of other countries, and that it is limited by the system, even if it is the most experienced in some types of Japanese specialists. Hospitals cannot be reflected in advertisements, making foreign patients unfamiliar with Japanese medical resources. However, as the government relaxes its visa policy, the market will further increase its volume in the future.

When talking about the establishment of a joint venture company, Muto said that Integrity Healthcare had accumulated a lot of high-quality medical resources in Japan before, and cooperated with many top medical institutions and clinicians in Japan. And as Japan’s current largest telemedicine service provider, it is expected to expand its telemedicine to cross-border telemedicine services in the future.

In addition to Integrity Healthcare, Muto also founded CHCP and Yu Home Clinic. The former mainly operates hospitals and pharmacies, while the latter applies IT technology to home medical care. The company has developed homes based on robotics and sensor technology. Medical support system to realize informatization of patient care and family medical team.

For MORE Health’s love for doctors,ntegrity Healthcare establishes a joint venture company, which can further expand its business scope while deepening the US market, copying its mature experience accumulated in cross-border medical services to the US on second opinion and referral services to Japan In the market. Integrity Healthcare has accumulated a lot of experience in telemedicine services, hospital operations, and doctor cooperation, and has built a reputation for accelerating the pace of landing.

Muto Shinto said of the future strategic plan of the joint venture company that the joint venture company will connect more excellent medical institutions and doctor resources in Japan to strengthen Chinese consumers’ awareness of Japanese medical treatment.

In the future, the joint venture company will further promote MORE Health’s well-established international consultation platform in Japan. “When we promoted in Japan before, we have been highly praised by doctors. Next, we want to further promote the platform in Japanese hospitals and incorporate it into the Japanese medical service system.”

Integrity Healthcare will also promote its achievements in Japanese disease management in China through a joint venture. “Patients can submit various body data through a portable device after surgery. In the future, we envision that patients will continue to use it when they return to China to achieve the purpose of follow-up.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2018; 68 (6): 394-424.

[2] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018. 391 (10125): 1023-1075.